{"doi":"10.1093/ndt/gfz106.fp369","title":"FP369ACF-TEI, a novel uremic toxin absorbent, has superior adsorption profiles and suppresses renal tubular injury induced by uremic toxins","abstract":null,"journal":"Nephrology Dialysis Transplantation","year":2019,"id":645742,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1681569,"name":"Takashi Shirakura","orcid":null,"position":1,"is_corresponding":false},{"id":1681570,"name":"Hiroshi Shimoyama","orcid":null,"position":2,"is_corresponding":false},{"id":1681571,"name":"Yasumi Nishiwaki","orcid":null,"position":3,"is_corresponding":false},{"id":1681572,"name":"Kumiko Aoki","orcid":null,"position":4,"is_corresponding":false},{"id":251515,"name":"Yoshimasa Takahashi","orcid":"0000-0001-6342-4087","position":5,"is_corresponding":false},{"id":1681573,"name":"Johji Nomura","orcid":null,"position":6,"is_corresponding":false},{"id":1681574,"name":"Tsunefumi Kobayashi","orcid":null,"position":7,"is_corresponding":false},{"id":1681568,"name":"Toshiya Mashiko","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"FP369ACF-TEI, a novel uremic toxin absorbent, has superior adsorption profiles and suppresses renal tubular injury induced by uremic toxins","abstract":"INTRODUCTION: Uremic toxins (UTs) such as Indoxyl sulfate (IS) have much attention as key factors in the progression of chronic kidney disease (CKD) and cardiovascular disease (CVD). UTs are produced in the liver from the precursors such as indole, which are derived from dietary protein. UTs accumulate in the blood and tissue in patients with impaired renal function, leading to induce uremic symptoms and organ dysfunction. In the kidney, IS accumulates into the renal proximal tubular cells via the organic anion transporter (OAT) 1 and OAT3, which results in inflammation/free radical production and fibrosis. Spherical activated carbon (AST-120) adsorbs UT precursors in the intestinal tract and excretes them out of the body with feces, leading to reduce UT level in the blood and tissue. Therefore AST-120 is effective in improving uremic symptoms and delaying the introduction to dialysis in CKD patients. However, the oral adsorbents comprising AST-120 have insufficient adsorption performance and need to be taken at high daily doses. Herein, we developed an active carbon fiber ACF-TEI, a novel oral UT adsorbent. In this study, we examined and compared in vitro adsorption profiles and in vivo efficacy of ACF-TEI with those of AST-120. We also evaluated the effects of ACF-TEI on renal tubular injury induced by IS in rat models. METHODS: As for the in vitro adsorption profiles to UT precursors, we examined the adsorption capacity and time course changes of ACF-TEI and AST-120. In in vivo studies, we compared the effects of ACF-TEI and AST-120 on serum and renal IS concentrations in bilateral nephrectomy rat (BNx) model and cisplatin-induced nephrotoxicity (CDDP) model. To evaluate the effects on tubular injury induced by UTs, we quantified the urinary excretion of KIM-1, a biomarker for renal proximal tubular injury in 5/6 nephrectomy rat (5/6Nx) model treated with IS. RESULTS: ACF-TEI showed more potent capacity and rapid adsorption profile than AST-120. ACF-TEI reduced serum and renal IS levels more potent than AST-120 in BNx model. ACF-TEI reduced serum and renal IS, and urinary excretion of KIM-1 in 5/6Nx model treated with IS. CONCLUSIONS: The adsorption capacity and efficiency of ACF-TEI were superior to those of AST-120 both in vitro and in vivo. In addition, ACF-TEI suppressed renal tubular injury induced by UTs in renal tubular injury model. Thus, ACF-TEI is expected to show more beneficial effects by suppressing renal tubular injury induced by UTs than AST-120 in clinical.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19910364","pmcid":null,"openalex_id":"https://openalex.org/W2951396236","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.11477704,"influential_citations":0,"citation_trend":[],"oa_status":"bronze","license":"https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model","oa_locations":[{"url":"https://academic.oup.com/ndt/article-pdf/34/Supplement_1/gfz106.FP369/28801501/gfz106.fp369.pdf","host_type":"journal"},{"url":"https://academic.oup.com/ndt/article-pdf/34/Supplement_1/gfz106.FP369/28801501/gfz106.fp369.pdf","host_type":"publisher"},{"url":"http://academic.oup.com/ndt/article-pdf/34/Supplement_1/gfz106.FP369/28801501/gfz106.fp369.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1093/ndt/gfz106.fp369","host_type":"journal"}],"fields_of_study":["Neurological and metabolic disorders"],"mesh_terms":[],"keywords":["Uremic toxins","Medicine","Toxin","Renal injury","Uremia","Urology","Internal medicine","Hemodialysis","Pharmacology","Kidney","Microbiology","Biology"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T10:00:15.830858Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}